Real-world effectiveness of oral antivirals for COVID-19.

Charles Burdet, Florence Ader

Abstract readComment

In one paragraph

Article in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality.Scientific reports · 2025
Article
The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability.Pharmaceutics · 2024
Article
COVID-19 pandemic sheds a new research spotlight on antiviral potential of essential oils - A bibliometric study.Heliyon · 2023
Review
Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19.Viruses · 2023
Article
Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study.Viruses · 2023
Article

4 · The record

Corrections and comments

Comment on
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.2022

5 · Who and what money

Authors and funding

2 authors.

Charles BurdetUniversité de Paris, IAME, INSERM, F-75018 Paris, France; Direction de santé publique et responsabilité populationnelle, Centre Intégré Universitaire de Santé et Services Sociaux de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, Québec, Canada.

Florence AderHospices Civils de Lyon, Hôpital de la Croix-Rousse, Département des Maladies Infectieuses et Tropicales, F-69004, 69004 Lyon, France; Université Claude Bernard Lyon 1, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, F-69372, Lyon, France. Electronic address: florence.ader@chu-lyon.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19 Drug TreatmentDermatologic AgentsAntiviral AgentsHumansAntiviral AgentsDermatologic Agents

Identifiers

PMID36215994

DOI10.1016/S0140-6736(22)01929-8

PMCPMC9539533

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.